ArticleCureus2025
A Rare Constellation of Triple Cutaneous Malignancies With Sustained Therapeutic Response: Kaposi Sarcoma, Basal Cell Carcinoma, and Cutaneous Squamous Cell Carcinoma in a Single Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The simultaneous occurrence of three distinct cutaneous malignancies - Kaposi sarcoma (KS), basal cell carcinoma (BCC), and cutaneous squamous cell carcinoma (cSCC) - in a single patient is exceptionally uncommon. We report the case of an 83-year-old male with cardiovascular comorbidities who was diagnosed with KS following histopathological confirmation (CD34⁺, ERG⁺, HHV-8⁺) and had a prior history of excised BCC and cSCC of the skin between 2020 and 2022. Over the course of his illness, he underwent multiple surgical resections, axillary lymph node dissection, systemic chemotherapy with paclitaxel, and immunotherapy. Despite eventual disease progression, he achieved sustained therapeutic benefit for more than 18 months, with clinical stabilization of lesions and meaningful palliation. This rare constellation underscores the diagnostic and therapeutic challenges of managing multiple primary skin malignancies in an immunosenescent patient. The coexistence of KS with keratinocyte carcinomas may reflect overlapping carcinogenic mechanisms, including viral oncogenesis (human herpesvirus-8 (HHV-8)), ultraviolet exposure, and immune dysregulation. Vigilant lesion-by-lesion biopsy, histopathological confirmation, and individualized multimodal management can achieve durable disease control and improved quality of life, even in elderly patients with complex dermatologic oncologic presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.